Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Alter Vego (AV) aims to create an extensive range of plant-based, customisable supplements. The company asserts that its production process is sustainable. It starts by creating a vegan protein base blend from ingredients such as pea, hemp, quinoa and brown rice that is ethically sourced and produced. It then develops daily sachets that contain Omega 3, B12, D3, K1, digestive enzymes, and probiotics to complement the base blend. AV argues that the sachets provide 100% of a user's Recommended Dietary Allowance (RDA) over any pre-mixed bulk blend. It aspires to become a contender in the global nutrition sector worth $702 billion. AV will use the investment for manufacturing and marketing its products across the UK.
days to go:
Expired
investment:
£46,455
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go:
Expired
investment:
£5,083,686
Cloud-based SaaS software with the purpose of efficiently generating corporate management reports to reduce operational costs and improve data quality. Synapse's service can be implemented into pre-existing financial reporting systems to produce automated reports, even in large companies. Customers include Lloyds Bank, who have signed a 2-year term and the Bank of England have contacted Synapse to potentially integrate the system.
days to go:
Expired
investment:
£894,056
Growth Capital Ventures (GCV) is a Financial Conduct Authority (FCA) approved fintech company. GCV's mission is to back the game changers, innovators and value creators. It is operating at three different levels namely, G-Ventures, a specialist software development division; Quva, a private investor network; and G- Labs, an innovation lab. The company aims to provide investors with access to well researched alternative investment opportunities that are selected for their potential to deliver better returns than traditional mainstream investment products. GCV has structured property transactions worth £14.7 million, has 5000+ everyday investors, and seen 500+ jobs created by portfolio companies. GCV will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,295,410
10Cast forensic forecasting is a cloud and mobile AI application that integrates with legacy CRM systems to improve B2B forecasting.
days to go:
Expired
investment:
£90,056
Software as a Service (SaaS) business for Recruitment generating recurring revenues on a scalable cloud platform. Used by HR, Recruiting Teams and HR Managers. Proven that we can sell to our target market we seek growth capital to build out our chosen go to market strategy.
days to go:
Expired
investment:
£280,000
